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Introduction: Tamoxifen, a selective estrogen receptor (ER) modulator, may affect cancer cell survival through
mechanisms other than ER antagonism. In the present study, we tested the efficacy of tamoxifen in a panel of
ER-negative breast cancer cell lines and examined the drug mechanism.
Methods: In total, five ER-negative breast cancer cell lines (HCC-1937, MDA-MB-231, MDA-MB-468, MDA-MB-453
and SK-BR-3) were used for in vitro studies. Cellular apoptosis was examined by flow cytometry and Western blot
analysis. Signal transduction pathways in cells were assessed by Western blot analysis. The in vivo efficacy of
tamoxifen was tested in xenograft nude mice.
Results: Tamoxifen induced significant apoptosis in MDA-MB-231, MDA-MB-468, MDA-MB-453 and SK-BR-3 cells,
but not in HCC-1937 cells. Tamoxifen-induced apoptosis was associated with inhibition of cancerous inhibitor of
protein phosphatase 2A (CIP2A) and phospho-Akt (p-Akt) in a dose-dependent manner. Ectopic expression of either
CIP2A or Akt protected MDA-MB-231 cells from tamoxifen-induced apoptosis. In addition, tamoxifen increased
protein phosphatase 2A (PP2A) activity, and tamoxifen-induced apoptosis was attenuated by the PP2A antagonist
okadaic acid in the sensitive cell lines, but not in resistant HCC-1937 cells. Moreover, silencing CIP2A by small
interfering RNA sensitized HCC-1937 cells to tamoxifen-induced apoptosis. Furthermore, tamoxifen regulated CIP2A
protein expression by downregulating CIP2A mRNA. Importantly, tamoxifen inhibited the in vivo growth of
MDA-MB-468 xenograft tumors in association with CIP2A downregulation, whereas tamoxifen had no significant
effect on CIP2A expression and anti-tumor growth in HCC-1937 tumors.
Conclusions: Inhibition of CIP2A determines the effects of tamoxifen-induced apoptosis in ER-negative breast
cancer cells. Our data suggest a novel “off-target” mechanism of tamoxifen and suggest that CIP2A/PP2A/p-Akt
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Breast cancer, a major worldwide health threat, is
considered to comprise a group of biologically hetero-
geneous diseases [1-3]. Breast cancer can be classified
into different subgroups by the expression of estrogen
receptor (ER), progesterone receptor (PR) and human
epidermal growth factor receptor 2 (HER2). These
subgroups present with distinct molecular backgrounds
and exhibit diverse clinical behavior and treatment
response [2,4]. Among all breast cancers, tumors with
negative expression of ER, which accounts for 25% to
30% of breast cancer [4,5], is known for its aggressive
nature and high metastatic potential [6]. Except for pa-
tients with the HER2-amplifying breast cancer subtype,
the mainstay treatment for patients with ER-negative
breast cancers is chemotherapy [7,8]; however, clinical
outcomes remain unsatisfactory [2]. Therefore, discovery
of novel therapeutic approaches is needed to advance
the treatment outcomes of patients with ER-negative
breast cancers.
Protein phosphatase 2A (PP2A) has been shown to be
an important tumor suppressor protein, and loss of PP2A
function has been identified in several malignancies, such
as lung, skin, colon, liver and breast cancers [9-11]. PP2A
functions as a serine/threonine phosphatase and has
been shown to regulate the activity of several oncogenic
proteins, such as c-Myc, extracellular signal-regulated
kinases and Akt, through direct dephosphorylation,
[9,12-14]. In breast cancer, PP2A has been shown to
prevent the oncogenic transformation of human breast
epithelial cells [13], and, conversely, mutant PP2A was
not found to be able to suppress the oncogenic activity
of RalA [15]. Recently, an emerging human oncoprotein
called cancerous inhibitor of PP2A (CIP2A) has been
shown to inhibit PP2A activity [16]. It is overexpressed
in many cancers, including breast cancer [17-22]. Import-
antly, CIP2A overexpression is associated with clinical
aggressiveness in human breast cancer and promotes the
malignant growth of breast cancer cells [17]. Interestingly,
the traditional chemotherapeutic agent doxorubicin has
been shown to downregulate CIP2A expression, and in-
creased CIP2A expression confers doxorubicin resistance
in breast cancer cells [23]. Moreover, in our recent studies,
we found that CIP2A is an important molecular determin-
ant of bortezomib-induced apoptosis in leukemia cells
[24] and in breast cancer cells [25]. Together, these data
suggest that CIP2A has an important role in breast cancer
cells and that targeting CIP2A could be a new therapeutic
approach.
Tamoxifen, a selective estrogen-receptor modulator, is
an important therapeutic agent for patients with ER-
positive breast cancers [26]. The antiestrogenic activity
of tamoxifen, by competing with estrogen for binding to
the ER in tumor tissue, is considered to be its coremechanism of action, and adjuvant use of tamoxifen
after primary resection of ER-positive breast tumor
decreases the risk of recurrence [27]. Interestingly, in
clinical trials, tamoxifen showed a 10% to 15% response
rate in tumors without ER expression [26,28]. Moreover,
adjuvant tamoxifen treatment after excision of breast
ductal carcinoma in situ (DCIS), a form of noninvasive
breast carcinoma, has been shown to reduce recurrent
risk, even in lesions without ER expression [8]. These
clinical findings suggest that tamoxifen has certain ER-
independent anticancer properties. Indeed, Blackwell
et al. found that tamoxifen could inhibit angiogenesis
in an ER-negative fibrosarcoma model [29]. Using the
ER-negative HeLa cell model, Obrero et al. found that
tamoxifen and its active metabolite could induce mitochon-
drial dysfunction and subsequently result in apoptotic cell
death [30]. Using a virtual screening approach, Rongmin
et al. found that 4-hydroxytamoxifen, the active metabol-
ite of tamoxifen, could cause activation of Hsp90 ATPase
at micromolar drug concentrations [31]. However, little
has been explored regarding the hormone-independent
effect of tamoxifen in breast cancer cells.
In this study, we report the apoptotic effect and mech-
anism of tamoxifen in ER-negative breast cancer cells.
We found that downregulation of CIP2A and phospho-
Akt (p-Akt) correlated with tamoxifen-induced apoptosis
in ER-negative breast cancer cells. Moreover, overexpres-
sion of CIP2A or Akt reduced the apoptotic effects in
tamoxifen-sensitive cells, whereas silencing CIP2A by
small interfering RNA (siRNA) sensitized resistant cells
to tamoxifen-induced apoptosis. Importantly, tamoxifen
inhibited in vivo xenograft tumor growth in association
with CIP2A downregulation. Therefore, tamoxifen induced
apoptosis through downregulating CIP2A/PP2A/p-Akt
signaling in ER-negative breast cancer cells.Methods
Reagents and antibodies
Tamoxifen, okadaic acid and forskolin for in vitro exper-
iments were purchased from Cayman Chemical (Ann
Arbor, MI, USA). Tamoxifen citrate tablets obtained from
AstraZeneca (London, UK) were used for in vivo animal
experiments. For in vitro studies, tamoxifen at various
concentrations was dissolved in dimethyl sulfoxide (DMSO)
and added to cells in Dulbecco’s modified Eagle’s medium
(Invitrogen, Carlsbad, CA, USA). The final DMSO concen-
tration was 0.1% after addition to the medium. Antibodies
for immunoblotting of CIP2A and ER-α, Ets1, Elk1 and
lamin B were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA, USA) for immunoblotting. Other anti-
bodies, such as Akt, p-Akt (Ser473), poly(ADP-ribose)
polymerase (PARP) and Myc-tag, were obtained from Cell
Signaling Technology (Danvers, MA, USA).
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The HCC-1937, MDA-MB-231, MDA-MB-468, MDA-
MB-453, SK-BR-3 and MCF-7 cell lines were obtained
from American Type Culture Collection (Manassas, VA,
USA). All breast cancer cells were maintained in Dulbecco’s
modified Eagle’s medium supplemented with 10% fetal
bovine serum, 0.1 mM nonessential amino acids, 2 mM L-
glutamine, 100 U/ml penicillin G, 100 μg/ml streptomycin
sulfate and 25 μg/ml amphotericin B in a 37°C humidified
incubator and an atmosphere of 5% CO2 in air. Lysates
of breast cancer cells treated with drugs at the indicated
concentrations for various periods of time were pre-
pared for immunoblotting of p-Akt, Akt, CIP2A and other
cells. Western blot analysis was performed as previously
reported [25].
Apoptosis analysis
Drug-induced apoptotic cell death was assessed using mea-
surement of apoptotic cells by flow cytometry (sub-G1
analysis of propidium iodide–stained cells) and Western
blot analysis of PARP cleavage.
Gene knockdown using small interfering RNA
SMARTpool siRNA reagents, including control (D-001810-
01) and CIP2A, were all purchased from Dharmacon
(Lafayette, CO, USA). The experimental procedure we
carried out has been cpoibed previously [25]. Briefly,
cells were transfected with siRNA (final concentration of
100 nM) in six-well plates using the liposome transfection
reagent Lipofectamine 2000 (Lipo2000; Invitrogen) accord-
ing to the manufacturer’s instructions. After 72 hours,
the medium was replaced and the breast cancer cells
were incubated with tamoxifen, harvested and separated
for Western blot analysis and apoptosis analysis by flow
cytometry.
Generation of MDA-MB-231 cells with constitutively active
Akt and MDA-MB-231 cells with constitutively active CIP2A
CIP2A cDNA (KIAA1524) was purchased from OriGene
(RC219918; Rockville, MD, USA) and constructed into a
pCMV6 vector. MDA-MB-231 cells were transfected with
Myc-tagged Akt1 construct or Myc-tagged CIP2A as pre-
viously described [24]. Briefly, following transfection,
cells were incubated in the presence of geneticin (G418,
1.40 mg/ml; Invitrogen). After 8 weeks of selection, surviv-
ing colonies (that is, those arising from stably transfected
cells) were selected and individually amplified.
Protein phosphatase 2A activity assay
The phosphatase activity of PP2A was detected by using
a commercial PP2A immunoprecipitation phosphatase
assay kit (EMD Millipore, Billerica, MA, USA) according to
the manufacturer’s instructions and as previously described
[24]. In brief, drug-treated or control cells were lysed, andPP2A was immunoprecipitated with anti-PP2A C subunit
antibodies and protein A agarose beads overnight. Protein
phosphatase activity of PP2A was determined by measuring
the generation of free phosphate from threonine phospho-
peptide using the malachite green phosphate complex
assay. To avoid variability due to differences in the amounts
of immunoprecipitated protein between samples, the
phosphatase activities were normalized to the amount
of PP2A immunoprecipitated, as detected and quantified
by immunoblot analysis for each treatment group.
Luciferase reporter constructs for the CIP2A promoter
and 5′ detection analysis
The upstream region of the CIP2A promoter containing
exon 1 (−2,000 bp to −1 bp) was amplified by PCR from
the genomic DNA of cells and cloned into the reporter vec-
tor, Firefly vector (pGL4.17; Promega, Madison, WI, USA)
by KpnI and BglII restriction sites. PCR-amplified promoter
regions −2,000/−1, −400/−1, −110/−1 and −62/−1 were
cloned into the KpnI and BglII restriction sites of the pGL4
basic vector. The nucleotide sequence of the clones was
verified by sequencing.
Dual-luciferase reporter assay
The promoter activity of CIP2A was determined using
the dual-luciferase reporter assay kit (Promega) according
to the manufacturer’s instructions. MDA-MB-468 cells
were cotransfected with the luciferase reporter constructs
pGL4.17-CIP2A-promoter (Firefly fluorescence reporter)
and PGL4.74-Renilla (Renilla fluorescence reporter) as
indicators for normalization of transfection efficiency.
Twenty-four hours posttransfection, cells were treated
with tamoxifen (5 μM) or DMSO for 24 hours. Cells
were then lysed and assayed for luciferase activity. The
promoter activity was repeated three times in parallel
for statistical analysis.
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation (ChIP) was performed
using the Pierce Agarose ChIP Kit (Pierce Biotechnology/
Thermo Fisher Scientific, Rockford, IL, USA) according
to the manufacturer’s instructions. Briefly, 1 × 107 MDA-
MB-468 cells were treated with tamoxifen 7.5 μM or
DMSO for 24 hours. Physical cross-linking between
chromatin (DNA) and proteins was fixed by 1% formal-
dehyde at room temperature for 10 minutes. Next, cells
were lysed for DNA by enzyme digestion (micrococcal
nuclease, 37°C, 15 minutes), and phosphatase inhibitor
and protease inhibitor were added in the cell lysis step
to avoid protein degradation. Lysates were clarified by
centrifugation at 12,500 × g for 5 minutes at 4°C. Immuno-
precipitation was performed by adding Elk1, Ets1 or rabbit
immunoglobulin G antibodies as the negative control.
The immunocomplex was precipitated by incubation
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4°C. The protein–DNA complex was eluted using 200 μl
of elution buffer from the beads. Cross-linking of protein–
DNA was reversed by adding 8 μl of 5 M NaCl at 95°C for
15 minutes. The DNA was purified using spin columns,
and 2 μl of the DNA was used in the semi-PCR for ampli-
fication of the CIP2A promoter region (−139/−16 bp).
Anti-RNA polymerase II antibody and glyceraldehyde
3-phosphate dehydrogenase (GAPDH) primers were pro-
vided by the manufacturer as a positive control for the
assay technique and reagent integrity.Xenograft tumor growth
The animal study was approved by the Institutional Animal
Care and Use Committee of Taipei Veterans General Hos-
pital. All experimental procedures using these mice were
performed in accordance with protocols approved by the
Institutional Animal Care and Use Committee of Taipei
Veterans General Hospital. Male NCr athymic nude mice
(5 to 7 weeks of age) were obtained from the National
Laboratory Animal Center (Taipei, Taiwan, Republic of
China). The mice were housed in groups and maintained
in a specific pathogen–free environment. Each mouse was
inoculated subcutaneously in the dorsal flank while under
isoflurane anesthesia with 5 × 106 breast cancer cells sus-
pended in 0.1 ml of serum-free medium containing 50%
Matrigel (BD Biosciences, San Jose, CA, USA). Tumors
were measured using calipers, and their volumes were cal-
culated using a standard formula: Width2 × Length × 0.52.
When tumors reached around 200 mm3, mice were orally
administered 100 mg/kg body weight tamoxifen citrate
three times weekly for 4 to 5 weeks. Controls received
vehicle (1× phosphate-buffered saline). Mice were killed
upon termination of treatment, and xenografted tumors
were harvested and assayed for molecular events by
Western blot analysis.RT-PCR
Total RNA was extracted from cultured cells using TRIzol
reagent (Invitrogen), and RT-PCR was performed according
to the manufacturer’s instructions (MBI Fermentas, Vilnius,
Lithuania). RT-PCR analyses were performed as previously
described [25] with specific primers for human CIP2A
(forward primer, 5′-TGGCAAGATTGACCTGGGATT
TGGA-3′; reverse primer, 5′-AGGAGTAATCAAAC
GvTGGGTCCTGA-3′; 172 bp), and the GAPDH gene
was chosen as an internal control (forward primer,
5′-CGACCACTTTGTCAAGCTCA-3′; reverse primer,
5′-AGGGGTCTACAT GGCAACTG-3′; 228 bp). qRT-
PCR was performed in a LightCycler 480 Instrument II
(Roche Diagnostics, Indianapolis, IN, USA) using a Light-
Cycler 480 SYBR Green I Master kit (Roche Diagnostics).
The primers were the same as those above described.Immunohistochemical staining
Paraffin-embedded breast cancer tissue sections (4 μm)
on poly-L-lysine-coated slides were deparaffinized and
rinsed with 10 mM Tris-HCl (pH 7.4) and 150 mM
sodium chloride. Peroxidase was quenched with methanol
and 3% hydrogen peroxide. Slides were then placed in
10 mM citrate buffer (pH 6.0) at 100°C for 20 minutes
in a pressurized heating chamber. After incubation with
a 1:200 dilution of p-Akt1/2/3 (Thr 308)-R antibody
(sc-16646-R; Santa Cruz Biotechnology) and with a 1:100
dilution of CIP2A antibody (ab84547; Abcam, Cambridge,
UK) for 1 hour at room temperature, slides were thor-
oughly washed three times with phosphate-buffered saline.
Bound antibodies were detected using the EnVision
Detection Systems Peroxidase/DAB, Rabbit/Mouse kit
(Dako, Glostrup, Denmark). The slides were then counter-
stained with hematoxylin. Paraffin-embedded sections
of mouse kidney tissue and human colon carcinoma were
used as positive controls for p-Akt1/2/3 and CIP2A,
respectively, as described in the datasheet from the
manufacturer. Negative controls had the primary antibody
replaced by phosphate-buffered saline. A board-certified
pathologist assessed the expression of p-Akt1/2/3 and
CIP2A semiquantitatively based on the intensity of stain-
ing. The intensity of staining was scored as negative, weak,
moderate and strong staining.
This study was approved by the ethics committee of the
Institutional Review Board of Taipei Veterans General
Hospital. All informed consents from sample donors were
in accordance with the Declaration of Helsinki and were
obtained at the time of donation.
Statistical analysis
Data are expressed as mean ± SD or SE. Statistical com-
parisons were based on nonparametric tests, and statistical
significance was defined as P < 0.05. For survival analysis,
progression-free survival curves of patients were gener-
ated using the Kaplan-Meier method and compared by
performing a logrank test. All statistical analyses were
carried out using SPSS for Windows software, version
12.0 (SPSS, Chicago, IL, USA).
Results
Differential apoptotic effects of tamoxifen on estrogen
receptor–negative breast cancer cells
To understand the antitumor effect of tamoxifen on
ER-negative breast cancer cells, we first assessed its
apoptotic effect in a panel of five ER-negative human
breast cancer cell lines: SK-BR3, MDA-MB-453, MDA-
MB-468, MDA-MB-231 and HCC-1937. First, negative
expression of ER in the cell lines was confirmed by
Western blotting (Figure 1A). Flow cytometric analysis of
sub-G1 cells showed that tamoxifen induced differential
apoptotic effects at the indicated times (24 and 36 hours)
Figure 1 Tamoxifen-induced apoptosis in association with downregulation of CIP2A and p-Akt in estrogen receptor–negative breast
cancer cells. (A) Differential cancerous inhibitor of protein phosphatase 2A (CIP2A) expression in five estrogen receptor (ER)–negative breast
cancer cell lines (SK-BR3, MDA-MB-453, MDA-MB-468, MDA-MB-231 and HCC-1937). MCF-7 was used as a positive control for ER expression.
(B) Dose and time escalation effects of tamoxifen on apoptosis in five ER-negative breast cancer cell lines. Cells were exposed to tamoxifen at the
indicated doses (1 μM, 2 μM, 5 μM, 7.5 μM and 10 μM) for 24 and 36 hours. Apoptotic cells were determined by flow cytometry (sub-G1 analysis
of propidium iodide–stained cells). Columns, Mean (n = 3); bars, SD. (C) Dose-dependent analysis of CIP2A, p-Akt and cleaved poly(ADP-ribose)
polymerase (PARP). Cells were exposed to tamoxifen at the indicated doses for 36 hours. Cell lysates were prepared and assayed for these molecules
by Western blotting. Data are representative of three independent experiments. Note that there was no significant tamoxifen-induced apoptosis in
HCC-1937 cells; only the PARP preform is presented.
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cell lines (Figure 1B). Tamoxifen induced apoptosis in a
dose- and time-dependent manner in MDA-MB-231,
MDA-MB-468, MDA-MB-453 and SK-BR3 cells, whereas
no apparent apoptotic effects were observed in HCC-1937
cells after tamoxifen treatment for 24 and 36 hours at
doses up to 10 μM (Figure 1B). These results suggest that
ER-negative breast cancer cell lines MDA-MB-231, MDA-
MB-468, MDA-MB-453 and SK-BR3 cells are sensitive to
the cytotoxic effect of tamoxifen, but that the HCC-1937
cell line is not.
Tamoxifen induces apoptosis in association with
downregulation of CIP2A and p-Akt in sensitive estrogen
receptor–negative breast cancer cells
We previously found that bortezomib induced apoptosis
in triple-negative (negative expression of ER, PR and
HER2) breast cancer cells through downregulation of
CIP2A and p-Akt, suggesting that CIP2A is a target of
bortezomib [25]. In this study, we investigated the
molecular events associated with apoptosis induced bytamoxifen in ER-negative breast cancer cells, with a
particular focus on CIP2A. As revealed in Figure 1C, in
the four tamoxifen-sensitive cell lines MDA-MB-231,
MDA-MB-468, MDA-MB-453 and SK-BR3, the protein
levels of CIP2A were downregulated by tamoxifen in a
dose-dependent manner. Moreover, inhibition of CIP2A
was associated with downregulation of p-Akt and in-
duction of apoptosis (evident by increased cleavage of
PARP). In contrast, the protein levels of CIP2A, p-Akt
and PARP were not significantly affected by tamoxifen
in HCC-1937 cells. The results suggest that inhibition
of CIP2A may play a major role in tamoxifen-induced
apoptosis in ER-negative breast cancer cells. We also
tested the effects of tamoxifen on CIP2A and p-Akt in
ER-positive MCF-7 cells (Additional file 1: Figure S1).
As shown in Additional file 1: Figure S1, tamoxifen also
induced apoptosis in association with CIP2A and p-Akt
downregulation in MCF-7 cells.
Tamoxifen has a well-established ERα-selective partial
agonist/antagonist function and can induce apoptotic as
well as antiproliferative effects, which raises the issue
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effects on CIP2A, p-Akt and apoptosis. In this regard,
we used fulvestrant (formerly ICI 182,780), a structural
analogue of estrogen with a pure antagonist function on
ERα, and tested the effects of fulvestrant in ERα-positive
MCF-7 cells and ERα-negative MDA-MB-453 cells. To
show the effect of fulvestrant on apoptosis in both ERα-
positive cells and ERα-negative cells, we used a relative
higher dose (1 μM) than the normally used doses (around
100 nM) for in vitro studies of ERα-positive cells [32].
As expected, both tamoxifen and fulvestrant could down-
regulate ERα in MCF-7 cells, a known effect contributing
to apoptosis (Additional file 1: Figure S2). In addition,
the CIP2A downregulation seemed more prominent in
MDA-MB-453 cells than in MCF-7 cells; however,
tamoxifen-induced apoptosis seemed higher in MCF-7
cells. Together our data show an “off-ERα” effect of
tamoxifen. Because a second estrogen receptor, ERβ,
has been found to be expressed in 50% to 90% of ERα-
negative breast cancers [33], we also checked the expres-
sion of ERβ in MCF-7 cells and ERα-negative cells and
found that these cells also showed positive ERβ expression
(Additional file 1: Figure S3).
Target validation of the CIP2A/PP2A/p-Akt pathway as a
molecular determinant of tamoxifen-induced estrogen
receptor–negative breast cancer apoptosis
To examine the role of CIP2A and p-Akt in mediating
tamoxifen-induced apoptosis, we generated MDA-MB-
231 cells with constitutive, ectopic expression of Myc-
tagged Akt (Figure 2A) or Myc-tagged CIP2A (Figure 2B).
Of note, MDA-MB-231 cells with constitutive, ectopic
expression of Myc-tagged Akt also expressed constitu-
tively activated p-Akt (Figure 2A). As shown in Figures 2A
and 2B, constitutive ectopic expression of either Myc-
tagged Akt or CIP2A protected sensitive MDA-MB-231
cells from apoptotic death induced by tamoxifen. Because
CIP2A is a cellular inhibitor of PP2A [16,24], we examined
the PP2A activity in tamoxifen-treated cells. As shown
in Figure 2C, tamoxifen significantly increased the phos-
phatase activity of PP2A in tamoxifen-sensitive cell lines
(Figure 2C). In addition, okadaic acid, a PP2A inhibitor
acting as a negative control, decreased the phosphatase
activity of PP2A in these four cell lines; however, forskolin,
a PP2A agonist acting as a positive control, increased
PP2A activity in these cells (Figure 2C). Moreover,
pretreatment with okadaic acid reduced the effects of
tamoxifen on apoptosis and p-Akt in tamoxifen-sensitive
MDA-MB-231, MDA-MB-468 and MDA-MB-453 cells
(Figure 2D), whereas cotreatment with forskolin sensitized
HCC-1937 cells to tamoxifen-induced apoptosis and p-
Akt downregulation (Figure 2E). We also checked PP2A
activity in these cells (Additional file 1: Figure S4). As
shown in the Additional file 1: Figure S4, forskolinincreased PP2A activity in HCC-1937 cells, and the com-
bination of tamoxifen and forskolin further increased
PP2A activity. Next, we performed knockdown of ex-
pression of CIP2A by using siRNA and found that
CIP2A siRNA sensitized the resistant HCC-1937 cells
to tamoxifen-induced apoptosis (Figure 2F). Notably,
depletion of CIP2A alone did not induce significant apop-
tosis in tamoxifen-resistant HCC-1937 cells (Figure 2F);
therefore, we further examined whether CIP2A siRNA
alone induced apoptosis in the tamoxifen-sensitive MDA-
MB-468 cells (Additional file 1: Figure S5). Similarly,
CIP2A siRNA alone did not induce significant apoptosis.
However, tamoxifen plus CIP2A siRNA induced signifi-
cantly more apoptosis as compared to tamoxifen treat-
ment (Additional file 1: Figure S5). It can be argued that
CIP2A downregulation per se may also participate in the
apoptosis mechanism. In this regard, we further tested the
effects of common chemotherapeutic agents for breast
cancers, including 5-fluorouracil (5-FU), paclitaxel and
docetaxel, and compared them with tamoxifen in MDA-
MB-468 cells (Additional file 1: Figure S6). We found that
only tamoxifen induced significant CIP2A reduction,
whereas all of these agents induced apoptosis in MDA-
MB-468 cells. Together, these results indicate that the
CIP2A/PP2A/p-Akt pathway plays a critical role in medi-
ating the apoptotic effect of tamoxifen in ER-negative
breast cancer cells.
Researchers in some studies have proposed other ER-
independent therapeutic potential of tamoxifen, such as
activation of Hsp90 [31]. Therefore, we performed coim-
munoprecipitation experiments with CIP2A and Hsp90
in tamoxifen-treated MDA-MB-468 cells, and we found
no apparent interactions between these two molecules
upon tamoxifen treatment (Additional file 1: Figure S7).
In addition, because PP2A comprises a large family of pro-
tein phosphatases known to affect apoptosis by regulating
multiple pro- or antiapoptotic proteins, such as c-Myc
and Bcl-2 [12]. It is possible that tamoxifen-induced
CIP2A inhibition could also affect cell survival through
dysregulation of PP2A substrates involved in apoptosis.
Accordingly, we checked the effects of tamoxifen on c-
Myc and Bcl-2 in tamoxifen-sensitive cells. Tamoxifen
showed differential effects on c-Myc and Bcl-2 in sensitive
cell lines (MDA-MB-468, MDA-MB-231, MDA-MD-453
and SK-BR3); it reduced c-Myc expression more promin-
ently in SK-BR3 cells; and it reduced Bcl-2 expression
more prominently in MDA-MB-231 cells (Additional
file 1: Figure S8).
Tamoxifen downregulates transcription of CIP2A in
estrogen receptor–negative breast cancer cells
To further study how tamoxifen affected CIP2A expression,
we first examined whether tamoxifen could affect CIP2A
elimination (degradation) when translation was blocked
Figure 2 CIP2A/PP2A/p-Akt mediated tamoxifen-induced apoptosis. (A) Ectopicexpression of myc-tagged Akt protected MDA-MB-231 cells
from tamoxifen-induced apoptosis. (B) Ectopic expression of myc-tagged CIP2A protected MDA-MB-231cells from tamoxifen-induced apoptosis.
Note that cells with ectopic expression of myc-tagged CIP2A also had constitutively high p-Akt. For experiments (A) and (B), cells were
transfected as described in Material and Methods. Control cells were empty-vector cells. Apoptosis was analyzed by flow cytometry after cells
were sequentially exposed to DMSO or tamoxifen at the indicated doses for 36 hours. (C) Analysis of PP2A activity in drug-treated cells. Cells
were treated with DMSO ortamoxifen at 7.5 μM or okadaic acid at 20 nM (as a negative control) or forskolin 40μM (as a positive control) for 36
hours. Cell lysates were assayed for PP2A activity. (D) Pretreatment of PP2A inhibitor okadaic acid protected cells from tamoxifen-induced
apoptosis. Cells were treated with DMSO (control) or tamoxifen (7.5 μM) for 36 hours. For pretreatment, cells were pretreated with okadaic acid
(20nM) for 1 hour; then they were washed and treated with tamoxifen (7.5 μM) for 36hours. Cell lysates were separated and assayed for sub-G1
analysis and westernblotting. (E) Cotreatment of tamoxifen with forskolin enhanced apoptosis in resistant HCC-1937 cells. Cells were treated with
DMSO (control), tamoxifen (7.5 μM), or co-treated with tamoxifen (7.5 μM) and forskolin (40 μM) for 36 hours. Cell lysates were separated and
assayed for sub-G1 analysis and western blotting. (F) Downregulation of CIP2A by siRNA increased tamoxifen-induced apoptosis in HCC-1937
cells. Cells were transfected with either control (scrambled siRNA) or CIP2A siRNA for 72 hours followed by exposure to tamoxifen at 7.5 μM for
36 hours. For (A) to (F), Columns, mean (n = 3); bars, SD; *P< 0.05.
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showed that after protein translation was blocked by cy-
cloheximide, the rate of CIP2A degradation did not
change significantly with or without tamoxifen treatment
in MDA-MB-231 and MDA-MB-468 cells (Figure 3A).
This implies that the effect of tamoxifen on CIP2A may
occur at the pretranslation level. We next investigated
whether tamoxifen affected CIP2A transcription via quan-
titative RT-PCR analysis. As shown in Figure 3B, CIP2A
mRNA levels decreased in a dose-dependent manner
upon treatment with tamoxifen in sensitive MDA-MB-
231, MDA-MB-468 and MDA-MB-453 cells, but not in
resistant HCC-1937 cells (Figure 3B). These results
indicate that tamoxifen inhibited CIP2A transcription,
and failure of this inhibition suggests tamoxifen resistance
in ER-negative breast cancer cells.To further decipher the possible mechanism how
tamoxifen reduced CIP2A mRNA, we presumed that
tamoxifen may affect CIP2A promoter activity through
transcription factors because researchers in previous
studies have unraveled several transcriptional regulators of
CIP2A promoter [34,35]. Accordingly, MDA-MB-468 cells
were transfected with luciferase reporter constructs for
CIP2A promoter of varying lengths (Figure 3C). As shown
in Figure 3C, tamoxifen significantly downregulated the
activity of CIP2A promoter in cells transfected with
constructs of −1 to approximately −2,000 bp and −1 to
about −400 bp, but tamoxifen did not reduce CIP2A
promoter activity in cells transfected with constructs of −1
to approximately −110 and −1 to about −62 bp. According
to previous studies [34,35], Ets1 and Elk1 could bind to
promoter regions between −400 and −110 bp. Next, we
Figure 3 Tamoxifen downregulated transcription of CIP2A. (A) After cells were treated with 100 μg/ml translation inhibitor cycloheximide (CHX)
in the presence (left) or absence (right) of tamoxifen (7.5 μM) for the indicated periods, the stability of CIP2A protein in whole-cell lysates was assessed
by Western blot analysis. In tamoxifen-sensitive cells, the addition of tamoxifen did not affect CIP2A degradation. (B) Tamoxifen affects CIP2A
transcription. Cells were treated with tamoxifen at the indicated doses for 36 hours, after which total RNA was isolated and CIP2A mRNA was assayed
by quantitative RT-PCR. Columns, mean values (n = 3); bars, SD. GAPDH, glyceraldehyde 3-phosphate dehydrogenase. (C) Identification of CIP2A
proximal promoter regions that were affected by tamoxifen treatment. MDA-MB-468 cells were transfected for 24 hours with Firefly luciferase reporter
vectors carrying CIP2A promoters of different lengths and Renilla vectors and then treated for 24 hours with 5 μM tamoxifen or DMSO. Cell lysates
were then assayed for dual-luciferase activity as described in the Methods section. Columns, mean values (n = 3); bars, SD; *P < 0.05. (D) Tamoxifen
disturbed binding of Elk1 to the CIP2A promoter region. Chromatin immunoprecipitation assays of the CIP2A promoter were performed as described
in the Methods section. Soluble chromatin was immunoprecipitated with Elk1, Ets1 or immunoglobulin G (negative control (NC)) antibodies.
Immunoprecipitates were subjected to PCR with primer pairs specific to CIP2A promoter (−16 to −139 bp). The gel shown is representative of three
independent experiments. Anti-RNA polymerase II antibody and GAPDH primers were used as a positive control (PC). (E) Tamoxifen affected Elk1
expression. Nuclear and cytoplasmic extracts were prepared from MDA-MB-468 cells treated with tamoxifen (7.5 μM) or DMSO for 24 hours. Cell lysates
were examined by Western blotting for Elk1. Lamin B and tubulin were used as loading controls.
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http://breast-cancer-research.com/content/16/5/431performed ChIP assays (Figure 3D) to examine whether
the binding of Ets1 or Elk1 (or both) to CIP2A promoter
is affected by tamoxifen. We found that tamoxifen dis-
turbed the binding of Elk1 to CIP2A promoter. Further
Western blot analysis for Elk1 in nuclear/cytoplasmic
extracts from MDA-MB-468 cells treated with or without
tamoxifen revealed that tamoxifen reduced Elk1 expression
in the nuclear extracts (Figure 3D). These data suggest
that tamoxifen may downregulate CIP2A transcription
by affecting Elk1.Effect of tamoxifen on estrogen receptor–negative breast
cancer xenograft tumor growth in vivo
To confirm that using tamoxifen to inhibit CIP2A has
potentially clinically relevant implications in ER-negative
breast cancer, we next used ER-negative breast cancer
xenograft models to evaluate the effect of tamoxifen
in vivo. Mice with MDA-MB-468- and HCC-1937-
xenografted tumors were generated to validate the role
of CIP2A in vivo. After successfully establishing the
xenograft model in nude mice, these tumor-bearing mice
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vehicle (as control) orally three times per week for 4 to
5 weeks. As shown in Figure 4A, tamoxifen inhibited
MDA-MB-468 tumor growth significantly, whereas HCC-
1937 tumor growth was not affected. Furthermore, theFigure 4 In vivo effect of tamoxifen on human breast cancer cell lines in
MDA-MB-468 tumors (left) but did not affect HCC-1937 tumor cell growth (rig
100 mg/kg body weight tamoxifen citrate administered orally three times we
Methods section. (B) Western blot analysis of the expression levels of cancero
Akt in MDA-MB-468 and HCC-1937 xenografts treated with control or tamoxif
HCC-1937 (bottom) tumors. Points, mean values (n = 6); bars, SD. (D) Schema
PP2A pathway. By inhibiting CIP2A, tamoxifen restores protein phosphatase 2
cell apoptosis.protein expression of CIP2A, p-Akt and Akt were checked
to confirm the correlation between the biological response
observed in vivo and the molecular mechanism discovered
in vitro (Figure 4B). Tamoxifen inhibited the expression of
CIP2A and p-Akt consistently in the three representativexenograft nude mice. (A) Tamoxifen treatment decreased the size of
ht). Points, mean values (n = 6); bars, SE; *P < 0.05. Mice received either
ekly or vehicle (1× phosphate-buffered saline), as described in the
us inhibitor of protein phosphatase 2A (CIP2A), phospho-Akt (p-Akt) and
en. (C) Body weight of xenograft mice bearing MDA-MB-468 (top) and
of the molecular mechanism of the action of tamoxifen on the CIP2A/
A (PP2A) activity downregulating p-Akt and leading to subsequent
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seen in the control (vehicle-treated) tumors (Figure 4B,
left panel). In the HCC-1937 tumors, the expression of
CIP2A and p-Akt were not affected in either the
tamoxifen- or control-treated tumors (Figure 4B, right
panel). At the end of the experiment, all the animals had
tolerated the treatments quite well without observable
signs of toxicity and had stable body weights throughout
the whole treatment course (Figure 4C). A schema
summarizing the molecular mechanism of tamoxifen in
sensitive ER-negative breast cancer cells is presented in
Figure 4D. Tamoxifen inhibited CIP2A, restored PP2A
activity and led to p-Akt downregulation and cancer
cell apoptosis (Figure 4D).
Expression of CIP2A correlates with expression of
p-Akt in breast tumor tissue from patients with estrogen
receptor–negative breast cancers
In four representative breast tumor tissues from patients
with ER-negative breast cancers with varying degrees
(negative, weak, moderate and strong staining) of CIP2A
expression, immunohistochemical staining for p-Akt
showed that the intensity of nuclear expression for p-
Akt correlated with cytoplasmic staining for CIP2A
(Figures 5A to 5D). Our previous data showed that 50
(87.7%) of 57 tumor samples from triple-negative breast
cancer patients demonstrated variable CIP2A expressionFigure 5 Immunohistochemical intensity of nuclear expression for p-Ak
representative immunohistochemical patterns of p-Akt in estrogen receptor (
expression (A), moderate nuclear expression (B), mild nuclear expression (C) a
was noted. Lower panel shows representative immunohistochemical patterns
showing strong cytoplasmic expression (A), moderate cytoplasmic expression
(D). Original magnification in upper and lower panels, 200×. (E) Left: CIP2A an
breast cancers (see Tables 1 and 2 for details). Right: Progression-free survival
moderate to low or negative CIP2A expression (n = 103). Curves were genera
logrank test.levels [25]. A recent immunohistochemistry-based study
demonstrated that CIP2A signature clustered with basal-
type and HER2-positive breast cancer signatures and
suggested that CIP2A is linked to these two subtypes of
breast cancer [36]. To study the clinical significance of
CIP2A, we further examined CIP2A and p-Akt expression
in tumor samples from 123 patients with ER-negative
breast cancers (including 53 (43.1%) with HER2-positive
breast cancers). As shown in Table 1, 96.7% of patients
had variable CIP2A expression levels (from low to high).
High expression of CIP2A was significantly correlated
with the patient’s clinical stage at diagnosis, as well as
with pathological microvascular invasion, but it was not
significantly associated with age or HER2 status (Table 2).
Survival analysis showed that patients with high CIP2A
expression had worse progression-free survival as com-
pared with patients with moderate to low or negative
CIP2A expression (Table 2, Figure 5E). Moreover, moder-
ate to high CIP2A expression correlated with high p-Akt
expression in these tumor samples (Figure 5E). The in vivo
result, therefore, supported the correlation of CIP2A and
p-Akt signaling found in vitro.
Discussion
In this study, we demonstrate the mechanism of action
of the drug tamoxifen in ER-negative breast cancer cells,
that is, induction of cancer cell apoptosis throught correlates with cytoplasmic staining for CIP2A. Upper panel shows
ER)–negative human breast cancer tissues showing strong nuclear
nd negative nuclear expression (D). No cytoplasmic expression of p-Akt
of cancerous inhibitor of protein phosphatase 2A (CIP2A) in cancer cells
(B), mild cytoplasmic expression (C), negative cytoplasmic expression
d p-Akt expression in tumor samples from 123 patients with ER-negative
curves for patients with high CIP2A expression (n = 20) and patients with
ted by using the Kaplan-Meier method and compared by performing a
Table 1 General characteristics of primary tumor samples
from 123 patients with hormone receptor–negative
breast cancersa
Characteristic N = 123 %
Median age, yr (IQR) 54 (48 to 66)





Node-positive disease 57 47.3












Positive p-Akt expression 120 97.6
aCIP2A, Cancerous inhibitor of protein phosphatase 2A HER2, Human
epidermal growth factor receptor 2. bHER2-positive was defined as an
immunohistochemical staining score of 3+ or 2+ with gene amplification
shown by fluorescence in situ hybridization.
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http://breast-cancer-research.com/content/16/5/431CIP2A-dependent p-Akt downregulation. These findings
not only increase current understanding of the drug
mechanisms of tamoxifen but also support the rationale
of targeting CIP2A in future drug development for
ER-negative breast cancer.Table 2 Clinicopathological characteristics according to
CIP2A expressiona





n = 103 (%) n = 20 (%)




(stages III and IV)
23 (22.3) 11 (55.0) 0.011
Microvascular invasion 23 (22.3) 9 (45.0) 0.001
HER2-positiveb 47 (45.6) 6 (30.0) 0.337
High p-Akt expression 49 (47.6) 12 (60.0) 0.338
5-year PFSc 76.7% 55% 0.034
aCIP2A, Cancerous inhibitor of protein phosphatase 2A; HER2, Human epidermal
growth factor receptor 2; PFS, Progression-free survival. bHER2-positive was
defined as an immunohistochemical staining score of 3+ or 2+ with gene
amplification shown by fluorescence in situ hybridization. cMedian follow-up
period 50.5 months (IQR = 34.1 to 86.8).Our data clearly show an “off-ERα” effect of tamoxifen
(Figure 1 and Additional file 1: Figures S1 and S2). In
addition, we checked the expression of ERβ in MCF-7
and ERα-negative cells (Additional file 1: Figure S3).
Indeed, these cells showed positive ERβ expression. ERβ,
a second estrogen receptor, has been found to be
expressed in 50% to 90% of ERα-negative breast cancers
[33]. Although tamoxifen is believed to target ERα in
ER-positive breast cancers, this mixed agonist-antagonist
can also transactivate ERβ, raising the question whether
ERβ has a prognostic value for tamoxifen responsiveness/
resistance [37]. Clinical studies have shown ERβ expression
to be a good prognostic marker for tamoxifen respon-
siveness in both ER-positive and ER-negative breast
cancer patients [33,37-39]. In vitro studies have sug-
gested a tumor-suppressive role of ERβ, particularly in
ER-positive breast cancer cells [33,37]. Whether ERβ has
multiple distinct roles in ERα-negative breast cancers
needs further investigation. It would be interesting to see
whether ERβ plays a role in tamoxifen-induced effects on
CIP2A/PP2A/p-Akt mechanisms, which requires more
studies.
There is a growing body of evidence supporting the use
of CIP2A as an anticancer target [16-20,23-25,40-43].
Accordingly, several agents that inhibit CIP2A have
been identified, and some have demonstrated efficacy
against different cancer cells. In our previous studies, we
demonstrated that bortezomib, a proteasome inhibitor,
induced apoptosis via proteasome-independent inhibition
of CIP2A in triple-negative breast cancer cells [25], hepa-
tocellular carcinoma cells [44], leukemia cells [24] and
head and neck cancer cells [41]. Interestingly, erlotinib, as
well as its derivatives, could also promote cancer cell
death by affecting the same signaling pathway (CIP2A/
PP2A/p-Akt) [42,45]. In this study, we found that tamoxi-
fen, a selective estrogen antagonist, induced significant
cancer cell apoptosis in ER-negative breast cancer cells
(Figure 1B). We confirmed the role of the CIP2A/PP2A/
p-Akt signaling pathway in tamoxifen-induced apoptosis
in ER-negative breast cancer cells. Liang et al. found that
rabdocoetsin B, an herbal extract of Rabdosia coetsa,
also inhibited proliferation and induced apoptosis in
lung cancer cells through CIP2A-dependent p-Akt down-
regulation [43]. Recently, Jung et al. found that a tumor-
suppressive microRNA, miR-375, could suppress CIP2A
and CIP2A-dependent Myc protein levels in oral cancer
cells that resulted in inhibition of cancer cell proliferation,
migration and invasion [46]. Furthermore, Sung et al.
showed that when expression of CIP2A in tumor cells was
induced by IL-10, the aggressiveness of pulmonary adeno-
carcinoma was aggravated [47]. We conclude from current
evidence that CIP2A is an important molecule associated
with cancer cell survival and could be a potential anticancer
target in many malignant diseases.
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alone did not induce significant apoptosis in tamoxifen-
resistant HCC-1937 cells (Figure 2F). Similarly, CIP2A
siRNA alone did not induce significant apoptosis in
tamoxifen-sensitive MDA-MB-468 cells (Additional file 1:
Figure S5). In a previous study, Come et al. [17] showed
that CIP2A siRNA alone decreased the proliferation of
MDA-MB-231 cells and inhibited the growth of xenograft
MDA-MB-231 cells in vivo. However, Junttila et al. [16]
and Côme et al. [17] showed that CIP2A siRNA alone
does not induce significant apoptosis, but significantly
inhibits cell proliferation. Consistent with previous studies,
our data show depletion CIP2A per se is insufficient to in-
duce apoptosis, but plays a key role in mediating apoptosis
induced by several “CIP2A-ablating agents,” including
tamoxifen [25,42,44,45,48]. These results suggest CIP2A is
essential but not sufficient in mediating tamoxifen-
induced apoptosis. Alternatively, it can be argued that
CIP2A downregulation per se may also participate in the
apoptosis mechanism. We further tested the effects of
common chemotherapeutic agents for breast cancers,
including 5-FU, paclitaxel and docetaxel, compared
with tamoxifen in MDA-MB-468 cells (Additional file 1:
Figure S6). Interestingly, only tamoxifen induced signifi-
cant CIP2A reduction, whereas all these agents induced
apoptosis in MDA-MB-468 cells. More studies are needed
to elucidate whether and at which steps CIP2A downregu-
lation participates in the process of apoptosis.
Although most clinical evidence suggests that tamoxi-
fen is particularly effective for ER-positive breast cancer
because it acts by competitive inhibition of ER and
estrogen-regulated genes, which slows tumor progression
[26,49], a 10% to 15% response rate has been reported in
patients with ER-negative breast cancer [26]. Tamoxifen
has also been shown to provide some protection in
patients with ER-negative DCIS after resection [50,51].
Researchers in some other studies have proposed the
ER-independent therapeutic potential of tamoxifen, includ-
ing in antiangiogenesis [29], induction of mitochondrial
dysfunction [30] and activation of Hsp90 [31], but none
of these studies were conducted in breast cancer cells.
Moreover, we performed coimmunoprecipitation exper-
iments with CIP2A and Hsp90 in tamoxifen-treated
MDA-MB-468 cells and found no apparent interactions
between these two molecules upon tamoxifen treatment
(Additional file 1: Figure S7). In contrast with previous
studies, in our present study we explored the mechanism
of tamoxifen using ER-negative breast cancer cell lines
and identified a new mechanism of action of tamoxifen,
namely, CIP2A-dependent p-Akt inhibition. Our results
may partly explain why some ER-negative breast cancer
patients respond to tamoxifen [8,26,28]. Future studies
correlating response to tamoxifen with downregulation
and/or pretreatment expression levels of CIP2A in breastcancer patients may help to establish a clinical role for
CIP2A as a predictive factor in breast cancer. Further-
more, in our previous studies, we showed that bortezomib,
by inhibiting the CIP2A/PP2A/p-Akt pathway, could
sensitize hepatocellular carcinoma cells to an antihuman
death receptor 5 antibody, CS-1008 [48], and could en-
hance radiation-induced apoptosis in cervical cancer and
hepatocellular carcinoma cells [52]. Therefore, the poten-
tial application of the new CIP2A inhibitory mechanism
of tamoxifen as part of a combination treatment strategy
with other anti–breast cancer agents is worth further
investigation.
In addition, we checked the effects of tamoxifen on c-
Myc and Bcl-2 in tamoxifen-sensitive cells to see if
tamoxifen-induced CIP2A inhibition could also affect
cell survival through dysregulation of other PP2A sub-
strates that are involved in apoptosis (Additional file 1:
Figure S8). Interestingly, tamoxifen showed differential
effects on c-Myc and Bcl-2 in sensitive cell lines (MDA-
MB-468, MDA-MB-231, MDA-MD-453 and SK-BR3).
Tamoxifen reduced c-Myc expression more prominently
in SK-BR3 cells and reduced Bcl-2 expression more prom-
inently in MDA-MB-231 cells. Compared to the effects of
tamoxifen on p-Akt reduction, the p-Akt downregulation
was more consistent in sensitive cells and correlated better
with tamoxifen-induced apoptosis (Figure 1).
In the present study, we show that tamoxifen suppressed
CIP2A transcription, but did not affect the degradation
of CIP2A protein after treatment with cycloheximide
(Figure 3). These results suggest that tamoxifen affects
CIP2A at the pretranscription level. To further decipher
the possible mechanism of how tamoxifen affects CIP2A
mRNA, we performed experiments with CIP2A pro-
moter activity assay (Figure 3C), ChIP assay (Figure 3D)
and Western blotting for nuclear/cytoplasmic extracts
(Figure 3E). The results suggest that tamoxifen may
downregulate CIP2A transcription via affecting Elk1.
Further mechanistic study is needed.
The present study has some limitations. Although we
show here that ERα-negative cells are sensitive to apop-
tosis induction by tamoxifen, it must be noted that the
concentrations required to induce apoptosis in these
cells is higher than for ERα-positive cells. Our in vitro
data showed at 5 μM tamoxifen induced more apoptosis
in ERα-positive MCF-7 cells compared to that in ERα-
negative MDA-MB-453 cells (Additional file 1: Figure S2).
A previous study by Salami et al. revealed a similar result
in terms of apoptosis, in which MCF-7 cells responded to
a lower tamoxifen concentration (1 μM) in a comparison
with MDA-MB468 cells, which were mainly affected at a
higher dose (20 μM) [53]. The usual effective dose of
tamoxifen in humans is around 20 to 40 mg/day [26,54].
Previous studies have shown a tumoristatic effect of
tamoxifen on MCF-7 xenografted tumors in mice [55-58].
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have been relatively low [55-58]. In addition, tamoxifen
has been shown to affect cancer cell cycles at serum
concentrations of tamoxifen achieved in breast cancer
patients (about 1 μM) [55]. These data suggest that the
doses of tamoxifen in ERα-positive xenograft mice models
could inhibit cell proliferation rather than directly kill
cancer cells. The dose of tamoxifen (100 mg/kg mouse
body weight) used for xenografts of ERα-negative cells
(MDA-MB-468) in the present study is higher than that
used for xenografts of MCF-7 cells previously reported in
the literature. In a pharmacokinetic study, Robinson et al.
showed that repeated large oral doses (200 mg/kg/day for
6 days) of tamoxifen to athymic mice produced an array
of serum metabolites similar to that seen in breast cancer
patients [59]. Although our in vivo data show that tamoxi-
fen inhibited tumor growth and downregulated protein
levels of CIP2A in MDA-MB-468 xenograft tumors, we
did not observe markers of apoptosis or proliferation
and our results do not validate the role of CIP2A in
tamoxifen-induced apoptosis in vivo. In this regard, more
xenograft experiments using breast cancer cells with
overexpression or downregulation of CIP2A and involving
examination of apoptosis markers should be helpful.
Currently, the structural information of CIP2A is lacking,
and the exact molecular mechanism of PP2A inhibition by
CIP2A remains unclear; therefore, directly targeting CIP2A
is difficult. Our data show that forskolin, a PP2A activator,
sensitized HCC-1937 cells to tamoxifen-induced apoptosis
(Figure 2E and Additional file 1: Figure S4). Recent studies
have shown that pharmacologic restoration of PP2A tumor
suppressor activity by PP2A-activating drugs (PADs; for
example, forskolin, FTY720) effectively antagonizes cancer
development and progression [60]. Accordingly, Perrotti
et al. suggested the importance of PP2A as a druggable
tumor suppressor in light of the possible use of PADs
as anticancer agents [60].
Conclusions
We report that tamoxifen acts through CIP2A-dependent
downregulation of p-Akt-mediated, tamoxifen-induced
apoptosis in ER-negative breast cancer cells. Our results
support the potential of CIP2A as a therapeutic target
in breast cancer treatment. Further studies designed to
unravel the detailed molecular modification of CIP2A
by tamoxifen and its application in other cancer cell
types are warranted.
Additional file
Additional file 1: Figure S1. Effect of tamoxifen in MCF-7 cells. Cells
were exposed to tamoxifen at the indicated doses for 36 hours. Figure S2.
Effects of tamoxifen and fulvestrant on ERα and CIP2A. Cells were treated
with these agents at indicated doses for 36 hours. Fulvestrant waspurchased from Sigma-Aldrich (St Louis, MO, USA). Figure S3. Expression of
ERβ in MCF-7 and ERα-negative breast cancer cells. Figure S4. Cotreatment
of tamoxifen with forskolin enhanced PP2A activity in resistant HCC-1937
cells. Cells were treated with DMSO or tamoxifen (7.5 μM) or cotreated with
tamoxifen (7.5 μM) and forskolin (40 μM) for 36 hours. Columns, mean
values (n = 3); bars, SD; *P < 0.05. Figure S5. Downregulation of CIP2A by
siRNA increased tamoxifen-induced apoptosis in MDA-MB-468 cells. Cells
were transfected with either scrambled or CIP2A siRNA for 72 hours,
followed by exposure to tamoxifen for 36 hours. Columns, mean values
(n = 3); bars, SD; *P < 0.05. Figure S6. Effects of tamoxifen and common
chemotherapeutic agents on apoptosis associated with CIP2A expression.
Cells were treated with DMSO, tamoxifen (5 μM), 5-FU (40 μM), paclitaxel
(20 nM) or docetaxel (2 μM) for 36 hours and assayed for CIP2A and
apoptosis. Figure S7. Coimmunoprecipitation of CIP2A and Hsp90 in
MDA-MB-468 cells treated with or without tamoxifen for 36 hours.
Figure S8. Effects of tamoxifen on c-Myc and Bcl-2 expressions in
tamoxifen-sensitive ERα-negative breast cancer cells. Cells were treated
with DMSO or tamoxifen for 36 hours.
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